(Q37147844)

18 August 2017

1 reference

title

Renin inhibitors, clinical experience (English)

1 reference

18 August 2017

4

Carsten Tschöpe

1 reference

18 August 2017

1

Dirk Westermann

1 reference

18 August 2017

Heinz-Peter Schultheiss

series ordinal

3

object named as

Heinz-Peter Schultheiss

1 reference

18 August 2017

Roland Schmieder

2

1 reference

18 August 2017

publication date

25 April 2008

1 reference

Journal of Molecular Medicine

18 August 2017

published in

1 reference

18 August 2017

volume

86

1 reference

18 August 2017

issue

6

1 reference

18 August 2017

page(s)

691-695

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-008-0338-y

18 August 2017

exact match

0 references

cites work

Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial

1 reference

12 December 2020

A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein

1 reference

12 December 2020

Renin inhibition: what are the clinical perspectives?

1 reference

12 December 2020

Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis

1 reference

12 December 2020

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

12 December 2020

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

12 December 2020

Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments

1 reference

12 December 2020

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

12 December 2020

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

1 reference

12 December 2020

Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy

1 reference

12 December 2020

Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan

1 reference

12 December 2020

Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients

1 reference

12 December 2020

Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials

1 reference

12 December 2020

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

12 December 2020

Direct renin inhibition: focus on aliskiren

1 reference

12 December 2020

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

1 reference

12 December 2020

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

1 reference

12 December 2020

Is the angiotensin II Type 2 receptor cerebroprotective?

1 reference

12 December 2020

Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension

1 reference

12 December 2020

World Hypertension Day 2007

1 reference

12 December 2020

Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension

1 reference

12 December 2020

Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension

1 reference

12 December 2020

A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension

1 reference

12 December 2020

β-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects

1 reference

12 December 2020

Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin

1 reference

12 December 2020

Direct renin inhibition with aliskiren in hypertension and target organ damage

1 reference

12 December 2020

Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.

1 reference

12 December 2020

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

12 December 2020

10.1007/S00109-008-0338-Y

Identifiers

DOI

1 reference

18 August 2017

1 reference